Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 2, 2005, Pages 127-132

  Woodward, W A ^a   Wachsberger, P ^b   Burd, R ^b   Dicker, Adam P ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Hormonal therapy; Prostate cancer; Radiation therapy; VEGF

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CYTOKINE; CYTOSTATIC AGENT; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTIANDROGEN;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; HORMONE INHIBITION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR VASCULARIZATION; CELL HYPOXIA; MALE; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; CELL HYPOXIA; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 23944447685     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500779     Document Type: Review

References (73)

1. Crawford ED. Epidemiology of prostate cancer. Urology 2003; 62 2 (6 Suppl 1): 3-12.
2. Jemal A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
3. Sosa M, Sanguineti G. External beam radiotherapy as definitive treatment for prostate cancer. Minerva Urol Nefrol 2003; 55: 263-275.
4. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol 2003; 55: 219-238.
5. Gottschalk AR, Roach M. The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br J Cancer 2004; 90: 950-954.
6. Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor. Int J Cancer 1999; 80: 868-874.
7. Klagsbrun M, Soker S. VEGF/VPF: The angiogenesis factor found? Curr Biol 1993; 3: 699-702.
8. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996; 15: 165-176.
9. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997; 57: 1054-1057.
10. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endofitelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-693.
11. Fernandez A et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213.
12. Mabjeesh NJ et al. Androgens stimulate hypoxia-inducible factor I activation via autocrine loop of tyrosine kinase receptor/ phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9: 2416-2425.
13. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: 2330-2334.
14. Fukumura D et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-725.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
16. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
17. Harris AL. Antiangiogenesis for cancer therapy, Lancet 1997; 349 (Suppl 2): SII13-SII15.
18. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-427.
19. Albo D, Wang TN, Tuszynski GE Antiangiogenic therapy. Curr Pharm Des 2004; 10: 27-37.
20. Tortora G, Melisi D, Ciardiello F. Angiogenesis: A target for cancer therapy. Curr Pharm Des 2004; 10: 11-26.
21. Hashizume H et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-1380.
22. Fox SB et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993; 53: 4161-4163.
23. Lissbrandt IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997; 33: 38-45.
24. Weidner N, Sample JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
25. Gettman MT et al. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis. Urology 1998; 51: 79-85.
26. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res 2000; 20: 3791-3799.
27. Bono AV et al. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5: 123-127.
28. Silberman MA, Partin AW, Veltri RW, Epstein JL, Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772-779.
29. Duque JLF et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523-527.
30. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology 2003; 61: 765-769.
31. Borgstrom P et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35: 1-10.
32. Fox WD et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002; 8: 3226-3231.
33. Franck-Lissbrant I et al. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451-456.
34. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507-2511.
35. Haggstrom S, Lissbrant IF, Bergh A, Damber JE. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161:1620-1625.
36. Benjamin LE et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
37. Jain RK et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95: 10820-10825.
38. Lissbrant IF et al. Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 2004; 58: 57-65.
39. Mazzucchelli R et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45: 72-79.
40. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002; 62: 1931-1934.
41. Movsas B et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999; 53: 11-18.
42. Cvetkovic D et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001; 57: 821-825.
43. Kung AL et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6: 1335-1340.
44. Shweiki D, Itin A, Sofrer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
45. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
46. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
47. Krishnamachary B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63: 1138-1143.
48. Fukuda R et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 38205-38211.
49. Maity A et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000; 60: 5879-5886.
50. Zhong H, Semenza GL, Simons JW, De Marzo AM. Upregulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28: 88-93.
51. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-1971.
52. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997; 3: 31-36.
53. Gorski DH et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998; 58: 5686-5689.
54. Gorski DH et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-3378.
55. Abdollahi A et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumour cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63: 3755-3763.
56. Gupta VK et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002; 8: 47-54.
57. Hess C et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001; 85: 2010-2016.
58. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333-13340.
59. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995; 77: 638-643.
60. Forsythe JA et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
61. Zhong H et al. Increased expression of hypoxia inducible factor 1alpha in rat and human prostate cancer. Cancer Res 1998; 58: 5280-5284.
62. Gao N et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 2002; 277: 31963-39171.
63. Gao N et al. p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem 2002; 277: 45041-45048.
64. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262-269.
65. Coleman CN. Hypoxia in tumors: A paradigm for the approach to biochemical and physiological heterogeneity. J Nat Cancer Inst 1988; 80: 310-317.
66. Movsas B et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 2000; 89: 2018-2024.
67. Wouters BG et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38: 240-257.
68. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449-6645.
69. Yuan F et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93: 14765-14770.
70. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF Development 1998; 125: 1591-1598.
71. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56: 4264-4266.
72. Lichtenbeld HC, Ferarra N, Jain RK, Munn LL. Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. Microvasc Res 1999; 57: 357-362.
73. Jain RK. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 2002; 29 (Suppl 16): 3-9.